![]() |
|||||
|
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() | |
![]() |
Gene: TEX2 |
Gene summary for TEX2 |
![]() |
Gene information | Species | Human | Gene symbol | TEX2 | Gene ID | 55852 |
Gene name | testis expressed 2 | |
Gene Alias | HT008 | |
Cytomap | 17q23.3 | |
Gene Type | protein-coding | GO ID | GO:0006629 | UniProtAcc | Q8IWB9 |
Top |
Malignant transformation analysis |
![]() |
![]() |
Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
55852 | TEX2 | P130T-E | Human | Esophagus | ESCC | 2.73e-23 | 4.65e-01 | 0.1676 |
55852 | TEX2 | NAFLD1 | Human | Liver | NAFLD | 5.18e-03 | 5.50e-01 | -0.04 |
55852 | TEX2 | HCC1_Meng | Human | Liver | HCC | 2.98e-30 | -6.80e-02 | 0.0246 |
55852 | TEX2 | HCC2 | Human | Liver | HCC | 2.76e-02 | 2.54e+00 | 0.5341 |
55852 | TEX2 | S016 | Human | Liver | HCC | 2.10e-04 | 2.25e-01 | 0.2243 |
55852 | TEX2 | S028 | Human | Liver | HCC | 3.71e-02 | 2.71e-01 | 0.2503 |
Page: 1 2 3 |
![]() |
∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
![]() |
![]() |
Tissue | Disease Stage | Enriched GO biological Processes |
Colorectum | AD | ![]() |
Colorectum | SER | ![]() |
Colorectum | MSS | ![]() |
Colorectum | MSI-H | ![]() |
Colorectum | FAP | ![]() |
∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
Page: 1 2 3 4 5 6 7 8 9 |
![]() |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:0048193 | Colorectum | AD | Golgi vesicle transport | 109/3918 | 296/18723 | 1.80e-10 | 1.68e-08 | 109 |
GO:0006888 | Colorectum | AD | endoplasmic reticulum to Golgi vesicle-mediated transport | 44/3918 | 130/18723 | 4.13e-04 | 4.68e-03 | 44 |
GO:00481931 | Colorectum | SER | Golgi vesicle transport | 79/2897 | 296/18723 | 4.20e-07 | 2.15e-05 | 79 |
GO:00068881 | Colorectum | SER | endoplasmic reticulum to Golgi vesicle-mediated transport | 34/2897 | 130/18723 | 1.13e-03 | 1.29e-02 | 34 |
GO:00481932 | Colorectum | MSS | Golgi vesicle transport | 101/3467 | 296/18723 | 9.09e-11 | 9.77e-09 | 101 |
GO:00068882 | Colorectum | MSS | endoplasmic reticulum to Golgi vesicle-mediated transport | 44/3467 | 130/18723 | 2.17e-05 | 4.60e-04 | 44 |
GO:00068883 | Colorectum | MSI-H | endoplasmic reticulum to Golgi vesicle-mediated transport | 22/1319 | 130/18723 | 1.05e-04 | 3.24e-03 | 22 |
GO:00481933 | Colorectum | MSI-H | Golgi vesicle transport | 39/1319 | 296/18723 | 1.17e-04 | 3.51e-03 | 39 |
GO:001623616 | Esophagus | HGIN | macroautophagy | 77/2587 | 291/18723 | 7.15e-09 | 4.61e-07 | 77 |
GO:002241120 | Esophagus | HGIN | cellular component disassembly | 102/2587 | 443/18723 | 8.31e-08 | 4.33e-06 | 102 |
GO:19030089 | Esophagus | HGIN | organelle disassembly | 36/2587 | 114/18723 | 8.60e-07 | 3.58e-05 | 36 |
GO:00619128 | Esophagus | HGIN | selective autophagy | 19/2587 | 68/18723 | 1.68e-03 | 1.85e-02 | 19 |
GO:001623617 | Esophagus | ESCC | macroautophagy | 216/8552 | 291/18723 | 1.94e-23 | 4.57e-21 | 216 |
GO:0022411111 | Esophagus | ESCC | cellular component disassembly | 305/8552 | 443/18723 | 1.94e-23 | 4.57e-21 | 305 |
GO:190300816 | Esophagus | ESCC | organelle disassembly | 89/8552 | 114/18723 | 1.36e-12 | 5.80e-11 | 89 |
GO:00066433 | Esophagus | ESCC | membrane lipid metabolic process | 130/8552 | 203/18723 | 9.29e-08 | 1.54e-06 | 130 |
GO:00066652 | Esophagus | ESCC | sphingolipid metabolic process | 96/8552 | 155/18723 | 3.21e-05 | 2.66e-04 | 96 |
GO:006191215 | Esophagus | ESCC | selective autophagy | 47/8552 | 68/18723 | 7.81e-05 | 5.80e-04 | 47 |
GO:00108765 | Liver | NAFLD | lipid localization | 79/1882 | 448/18723 | 4.75e-07 | 2.92e-05 | 79 |
GO:00068694 | Liver | NAFLD | lipid transport | 71/1882 | 398/18723 | 1.16e-06 | 5.59e-05 | 71 |
Page: 1 2 3 4 |
![]() |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
Page: 1 |
Top |
Cell-cell communication analysis |
![]() |
Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
![]() |
TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
![]() |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
TEX2 | SNV | Missense_Mutation | novel | c.735N>G | p.His245Gln | p.H245Q | Q8IWB9 | protein_coding | tolerated(0.4) | benign(0.227) | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEX2 | SNV | Missense_Mutation | c.463N>A | p.Glu155Lys | p.E155K | Q8IWB9 | protein_coding | tolerated(0.12) | benign(0.011) | TCGA-AC-A23H-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | PD | |
TEX2 | SNV | Missense_Mutation | novel | c.2848N>G | p.Leu950Val | p.L950V | Q8IWB9 | protein_coding | deleterious(0) | possibly_damaging(0.799) | TCGA-AC-A62Y-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
TEX2 | SNV | Missense_Mutation | novel | c.1000N>G | p.Leu334Val | p.L334V | Q8IWB9 | protein_coding | tolerated(0.39) | benign(0.122) | TCGA-Z7-A8R6-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | CR |
TEX2 | insertion | Frame_Shift_Ins | novel | c.707_708insAAAGAAAAAAAAAAGGCAAATACTAAGTGGAGGATTGGAGAAGTGG | p.Pro237LysfsTer18 | p.P237Kfs*18 | Q8IWB9 | protein_coding | TCGA-A2-A04Y-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | ||
TEX2 | insertion | Nonsense_Mutation | novel | c.736_737insATCAAGGAGGAGGAGTGTGATTCTGAGGGGGATGGCTACGG | p.Leu246HisfsTer7 | p.L246Hfs*7 | Q8IWB9 | protein_coding | TCGA-A8-A06X-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TEX2 | insertion | In_Frame_Ins | novel | c.1487_1488insCCTAGAACTTCTATTTATTATTATTTTTTT | p.Ser496_Gly497insLeuGluLeuLeuPheIleIleIlePhePhe | p.S496_G497insLELLFIIIFF | Q8IWB9 | protein_coding | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD | ||
TEX2 | insertion | Frame_Shift_Ins | novel | c.3006_3007insTGTGA | p.Lys1003CysfsTer65 | p.K1003Cfs*65 | Q8IWB9 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TEX2 | insertion | In_Frame_Ins | novel | c.3005_3006insTGATGAGTTCAGCATCACTGC | p.Thr1002_Lys1003insAspGluPheSerIleThrAla | p.T1002_K1003insDEFSITA | Q8IWB9 | protein_coding | TCGA-AN-A0FX-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD | ||
TEX2 | insertion | Nonsense_Mutation | novel | c.2022_2023insGTAAGTCTGGGTTGCCTTTGAAAGCTATGAATTGAGATATTTATGGTA | p.Pro674_Gln675insValSerLeuGlyCysLeuTerLysLeuTerIleGluIlePheMetVal | p.P674_Q675insVSLGCL*KL*IEIFMV | Q8IWB9 | protein_coding | TCGA-BH-A0B1-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | adriamycin | SD |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 |
Top |
Related drugs of malignant transformation related genes |
![]() |
(DGIdb 4.0) |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
Page: 1 |